ISIS PHARMACEUTICALS TRIMS 4Q LOSS
Biotech company Isis Pharmaceuticals
Inc. said on Thursday it dramatically narrowed its fourth-quarter loss, thanks
to a reduction in spending. Net loss applicable to shareholders for the quarter
was $7.9 million, or 11 cents per share, narrowed from $57.5 million, or $1 per
share, a year ago. Revenue for the quarter grew nearly 29 percent to $14.6 million,
up from $11.4 million in the previous year.